City Therapeutics CTY

$18.10

−4.64%

Nov 13

Activities

RNA silencing drugs

Cardiovascular drugs

AI analysis

Posts

City Therapeutics

2w ago · 5% stake

Notable

ARCH Venture Fund XII declares 25.6% of newly listed City Therapeutics

ARCH Venture Fund XII, a venture capital fund, holds 25.6% of City Therapeutics after its stock market debut and says it holds the shares for investment.

CTY

About City Therapeutics, Inc. Common Stock

City Therapeutics is a clinical-stage biotech that develops RNA interference drugs, which switch off disease-causing genes in the liver. Its pipeline includes CITY-FXI for blood clots, CITY-RBP4 for Stargardt disease and CITY-TFR2 for anemia. It has no product revenue and funds its research with investor money and partner payments.